Invest In Genetic Eye Testing For AMD:

Know your risk and get tested NOW before it’s too late!

Visible Genomics is a leading genetics company focused on age-related macular degeneration, the primary cause of legal blindness. Early genetic detection of a predisposition marker and swift intervention is critical in order to delay the possible onset of AMD or its advancement. A Global Market Opportunity – Potential +$1 Billion TAM.  The genetic testing market is poised to reach over $36 Billion by 2030, growing at a CAGR of over 10%.


Visible Genomics Is Serving A Huge, Unmet Need:
  • Up to 71% of AMD is due to genetics, 2X the link vs breast and colon cancers. 
  • Nearly 20 million people in the U.S. are living with some form of AMD, with 35 million more people at risk as a consequence of exponential population aging. 
  • 196 million AMD patients globally, is expected to reach 288 million worldwide by 2040.
  • Recommended target age group to take initial DNA eye test starting from age 40 and above, but no later than age 50!
Reasons To Invest In Visible Genomics:

Advanced DNA Technology: Developed by its genetic and research bioinformatics team, Visible Genomic’s  AMDiGuard™ is a simple, quick and cost-effective cheek swab test to collect DNA for processing by a compliant CLIA lab for analysis that provides a comprehensive genetics-based risk assessment utilizing proprietary algorithms. 

Huge Market and Growth Potential: AMDiGuard™ is currently being sold to eye-care professionals and direct-to-consumers. The company estimates the U.S. TAM range from $72.6 million to $430 million, with a potential added growth into worldwide markets from $399 million to $2.3 billion.

Pharma and Life Science Collaboration: Sharing data, outcome measurements and working with pharma and nutraceutical companies to develop and design new drugs and vitamins to help patients fight against ocular diseases.

New Tests for Other Ocular Diseases: Positioned to introduce new DNA tests for Glaucoma and Diabetic Retinopathy, along with a premium singular DNA test for all ocular diseases. 

Strong Team: Relationships with leading eye-care professionals, scientific genetic team, advisory board, and key opinion leaders.  Developing key partnerships with strategic eye-care industry marketing groups to accelerate sales growth. The management team is made up of seasoned professionals.

View Pitch Deck

Interested? Let us know.